Mercury Laboratories Ltd
Incorporated in 1962, Mercury Laboratories Ltd manufactures and exports Pharmaceutical
items of gyno and pediatrics.[1]
- Market Cap ₹ 91.5 Cr.
- Current Price ₹ 762
- High / Low ₹ 943 / 621
- Stock P/E 20.8
- Book Value ₹ 484
- Dividend Yield 0.46 %
- ROCE 12.1 %
- ROE 9.17 %
- Face Value ₹ 10.0
Pros
Cons
- The company has delivered a poor sales growth of 2.05% over past five years.
- Company has a low return on equity of 8.84% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 41.19 | 47.51 | 48.02 | 51.86 | 55.52 | 57.27 | 68.60 | 57.92 | 75.33 | 75.56 | 75.10 | 75.94 | 73.76 | |
| 35.40 | 41.04 | 41.30 | 47.44 | 49.79 | 51.10 | 59.01 | 50.92 | 66.73 | 66.53 | 68.08 | 66.91 | 65.88 | |
| Operating Profit | 5.79 | 6.47 | 6.72 | 4.42 | 5.73 | 6.17 | 9.59 | 7.00 | 8.60 | 9.03 | 7.02 | 9.03 | 7.88 |
| OPM % | 14.06% | 13.62% | 13.99% | 8.52% | 10.32% | 10.77% | 13.98% | 12.09% | 11.42% | 11.95% | 9.35% | 11.89% | 10.68% |
| 1.12 | 0.78 | 0.35 | 0.42 | 1.04 | 0.85 | 0.88 | 0.94 | 1.69 | 1.09 | 1.07 | 1.57 | 1.43 | |
| Interest | 1.12 | 1.13 | 0.89 | 0.91 | 1.09 | 0.82 | 0.64 | 0.45 | 0.36 | 0.38 | 0.55 | 0.54 | 0.52 |
| Depreciation | 1.18 | 1.18 | 1.29 | 1.47 | 1.63 | 1.87 | 1.92 | 2.45 | 2.48 | 2.82 | 2.88 | 3.42 | 3.30 |
| Profit before tax | 4.61 | 4.94 | 4.89 | 2.46 | 4.05 | 4.33 | 7.91 | 5.04 | 7.45 | 6.92 | 4.66 | 6.64 | 5.49 |
| Tax % | 27.98% | 20.45% | 44.79% | 17.89% | 29.88% | 25.40% | 32.49% | 29.17% | 24.97% | 18.35% | 32.62% | 27.11% | |
| 3.31 | 3.92 | 2.70 | 2.01 | 2.84 | 3.23 | 5.34 | 3.56 | 5.58 | 5.65 | 3.14 | 4.83 | 4.17 | |
| EPS in Rs | 27.58 | 32.67 | 22.50 | 16.75 | 23.67 | 26.92 | 44.50 | 29.67 | 46.50 | 47.08 | 26.17 | 40.25 | 34.75 |
| Dividend Payout % | 5.44% | 4.59% | 6.67% | 8.96% | 6.34% | 7.43% | 7.87% | 11.80% | 7.53% | 7.43% | 13.38% | 8.70% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 5% |
| 5 Years: | 2% |
| 3 Years: | 0% |
| TTM: | -4% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | -1% |
| 3 Years: | -3% |
| TTM: | 17% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | 3% |
| 3 Years: | -1% |
| 1 Year: | -10% |
| Return on Equity | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 10% |
| 3 Years: | 9% |
| Last Year: | 9% |
Balance Sheet
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 1.20 | 1.20 | 1.20 | 1.20 | 1.20 | 1.20 | 1.20 | 1.20 | 1.20 | 1.20 | 1.20 | 1.20 |
| Reserves | 16.94 | 20.65 | 23.27 | 25.15 | 27.77 | 30.78 | 35.69 | 39.11 | 44.43 | 49.64 | 52.37 | 56.88 |
| 8.88 | 7.37 | 7.44 | 9.76 | 9.56 | 7.19 | 7.10 | 5.99 | 5.83 | 5.55 | 5.45 | 8.42 | |
| 15.50 | 17.30 | 19.23 | 15.59 | 18.76 | 17.13 | 21.38 | 16.14 | 12.70 | 11.56 | 15.21 | 12.58 | |
| Total Liabilities | 42.52 | 46.52 | 51.14 | 51.70 | 57.29 | 56.30 | 65.37 | 62.44 | 64.16 | 67.95 | 74.23 | 79.08 |
| 19.48 | 18.57 | 18.39 | 20.78 | 24.39 | 23.66 | 26.36 | 25.82 | 24.26 | 24.03 | 24.64 | 23.89 | |
| CWIP | 0.00 | 0.00 | 0.40 | 0.24 | 0.00 | 0.00 | 0.00 | 0.00 | 0.13 | 3.82 | 9.32 | 9.82 |
| Investments | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| 23.03 | 27.94 | 32.34 | 30.67 | 32.89 | 32.63 | 39.00 | 36.61 | 39.76 | 40.09 | 40.26 | 45.36 | |
| Total Assets | 42.52 | 46.52 | 51.14 | 51.70 | 57.29 | 56.30 | 65.37 | 62.44 | 64.16 | 67.95 | 74.23 | 79.08 |
Cash Flows
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.49 | -0.10 | 1.92 | 4.97 | 5.22 | 5.49 | 8.21 | 5.19 | 2.45 | 8.23 | 4.00 | 4.24 | |
| -1.54 | -0.28 | -1.50 | -3.68 | -4.99 | -1.14 | -4.62 | -1.89 | -1.06 | -6.27 | -9.04 | -3.17 | |
| -2.12 | 0.47 | -0.25 | 1.07 | -2.54 | -3.33 | -1.24 | -1.23 | -1.01 | -1.04 | -0.99 | 2.63 | |
| Net Cash Flow | -0.18 | 0.09 | 0.17 | 2.36 | -2.31 | 1.02 | 2.36 | 2.07 | 0.38 | 0.91 | -6.03 | 3.71 |
| Free Cash Flow | 1.95 | -0.38 | 0.42 | 1.29 | 0.23 | 4.35 | 3.59 | 3.30 | 1.39 | 1.96 | -5.04 | 1.07 |
| CFO/OP | 82% | 20% | 45% | 129% | 109% | 109% | 100% | 101% | 41% | 105% | 91% | 61% |
Ratios
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 107.84 | 103.02 | 133.25 | 103.60 | 126.82 | 115.61 | 119.93 | 105.49 | 103.55 | 105.55 | 125.10 | 124.25 |
| Inventory Days | 93.92 | 115.50 | 137.30 | 119.80 | 93.95 | 78.44 | 60.42 | 104.59 | 82.82 | 75.88 | 92.47 | 88.01 |
| Days Payable | 159.39 | 136.34 | 186.56 | 138.65 | 161.71 | 120.01 | 137.94 | 105.98 | 76.58 | 63.30 | 126.07 | 77.13 |
| Cash Conversion Cycle | 42.37 | 82.19 | 83.99 | 84.75 | 59.05 | 74.04 | 42.41 | 104.10 | 109.79 | 118.13 | 91.50 | 135.12 |
| Working Capital Days | 9.22 | 46.86 | 102.84 | 90.58 | 88.75 | 88.78 | 75.02 | 79.02 | 87.02 | 91.64 | 110.86 | 130.16 |
| ROCE % | 21.35% | 21.59% | 18.91% | 9.82% | 13.77% | 13.26% | 20.56% | 11.83% | 16.04% | 13.41% | 8.94% | 12.06% |
Insights
In beta| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|
| Direct export share of total revenue % |
|
|||||||
| Export to Africa share of total exports % |
||||||||
| Export to Americas share of total exports % |
||||||||
| Export to Asia share of total exports % |
||||||||
| Number of permanent employees employees |
||||||||
| Manufacturing capacity (tablets) tablets per month |
||||||||
| Number of countries with direct export presence countries |
||||||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Change in Management
- Mercury Laboratories appoints Sunil Sharma as Head-Injectable Production; Seema Salvi resigns effective 21 August 2026.
-
Communication To Shareholders - Intimation On Tax Deduction On Dividend
- Board recommended Rs 3.5 dividend; record date 21 Sep 2026; shareholders must update PAN/KYC.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
- Newspaper advertisement of unaudited financial result for the quarter ended on June 2026 is attched
-
Unaudited Financial Results For The Quarter Ended On June 30, 2026
- Board approved Q1 FY27 unaudited results; net profit ₹29.78 lakh on ₹1,601.54 lakh income.
-
Board Meeting Outcome for Outcome Of The Board Meeting Held On July 25, 2026
- Board approved Q1 FY27 unaudited results; net profit rose to Rs 29.78 lakh.
Annual reports
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from bse
-
Annual Report 2012
from bse
-
Annual Report 2007
from bse
Business Overview:[1][2][3]
MLL is engaged in formulating, developing, manufacturing, exporting, marketing and distributing pharmaceutical
drugs and therapeutic compliance medicines. The products of the company are in the segment of gynae and pediatric. Its major brands are K-Win, K-Stat, T-Stat, Merizyme and Promolact